Ischaemic heart disease following renal transplantation

Nephrology Dialysis Transplantation

Volumn 15, Issue 2, 2000, Pages 269-277

  Stewart, Graham ^a   Jardine, Alan G ^a   Briggs, J Douglas ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

EID: 0033959316     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.2.269     Document Type: Article

References (61)

1. US Renal Data System. USRDS 1997 Annual Data Report. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1997
2. Aakhus S, Dahl K, Wideroe T. Cardiovascular morbidity and mortality in renal transplant reciients. Results from a 5 year follow-up. Nephrol Dial Transplant 1999; 14: 648-654
3. Lindholm A, Albrechtsen D, Frodin L, Turfveson G, Persson NH, Lundgren G. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-457
4. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal failure: where do we start? Am J Kid Disease 1998; 32 [suppl 3]: S5-S13
5. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular Disease after renal transplantation. J Am Soc Neph 1996; 7: 158-165
6. Vesco L, Busson M, Bedrossian J, Biitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation. Transplantation 1996; 61: 1475-1478
7. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependant diabetes mellitus. New Engl J Med 1993; 329: 977
8. Opelz G, Wujciak T, Ritz E for the collaborative transplant study. Association of chronic kidney graft survival with recipient blood pressure. Kidney Int 1998; 53: 217-222
9. Stewart GA, Tan CC, Rodger RSC, Jardine AG. New targets for blood pressure control post transplantation. J Am Soc Nephrol 1998; 9: (abstract A3567)
10. Stewart GA, McGregor EM, Briggs JD, Junor BJR, Jardine AG. Pre and post transplant echocardiographic abnormalities are predictors of survival. Kidney Int 1998; (abstract)
11. Mall G, Huther W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44
12. Rockstroh JK, Schobel HP, Vogt-Ladner G, Hauser I, Neumayer HH, Schmieder RE. Blood pressure independent effects of nitrendipine on cardiac structure in patients after renal transplantation. Nephrol Dial Transplant 1997; 12: 1441-1447
13. Verdechi P, Porcellati C, Schillachi G. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801
14. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AEG, Baker LRI. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 1997; 12: 724-728
15. Lipkin GW, Tucker B, Giles M, Raine AEG. Ambulatory blood pressure and left ventricular mass in cyclosporin and non-cyclosporin treated renal transplant recipients. J Hypertens 1993; 11: 439-442
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
17. Pyorala K, Pedersen TR, Kjekshus J et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998: 32; 140-146
18. Downs JR, Clearfield M, Weis S et al. for the AFCAPS/ TexCAPS Research group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J Am Med Assoc 1998; 279: 1615-1622
19. Sheperd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in patients with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-1307
20. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620
21. Jardine AG, Morris STW, Holdaas H. The use of statins in transplant recipients. Am J Cardiol (in press)
22. Holdaas H, Fellstrom B, Holme I et al. Multicentre, randomised, double blind, placebo-controlled study on the effects of Fluvaststin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in renal transplantation). Study design and baseline data. Kidney Int 1999; (abstract)
23. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281-2287
24. Attman PO, Samuelson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592
25. Ritz E, Benck U, Franek E, Keller C, Seyfarth M, Clorius J. Effects of smoking on renal haemodynamics in healthy volunteers and in patients with glomerular disease. J Am Soc Nephrol 1998; 9: 1798-1804
26. Woo YM, Jardine AJ, Clark AF et al. Early graft function and patient survival following cadaveric renal transplantation. Kidney Int 1999; 55: 692-699
27. Rodgers GM, Conn TM. Homocysteine, an atherogenic stimulus, reduces protein-C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901
28. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyslcinc and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881
29. Bostom AG, Gohh RY, Tsai MY, Hopkins-Garcia BJ, Nadeau MR, Bianchi LA. Excess prevalence of fasting and post-methionine loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thrombos Vasc Biol 1997; 17: 1894-1900
30. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflamation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New Engl J Med 1997; 336: 973-979
31. Yarnell JWG, Baker IA, Sweetnam PM. Fibrinogen, viscosity and white blood cell count are major risk factors for ischaemic heart disease: the Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991; 83: 836-844
32. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van der Loo JCW for the European concerted action on thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-641
33. Koch M, Kutkuhn B, Trenkwalder E et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein (a) phenotypes predict coronary artery disease in haemodialysis patients. J Am Soc Nephrol 1997; 8: 1889-1898
34. Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflamation enhances cardiovascular risk and mortality in haemodialysis patients. Kidney Int 1999; 55: 648-658
35. Bergstrom J, Heimburger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in haemodialysis (HD) patients. J Am Soc Nephrol 1995; 6: 573 (abstract)
36. Grady D, Rubin SM, Pettiti DM. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992; 117: 1016-1037
37. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the heart and estrogen/progestin replacement study (HERS) research group. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613
38. Ramos E, Kasiske B, Alexander S et al. The evaluation of candidates for renal transplantation. Transplantation 1994; 57: 490-497
39. Philipson J, Carpenter B, Itzkoff J, Hakala TR, Rosenthal JT, Taylor RJ, Puschett JB. Evaluation of cardiovascular risk for renal transplantation in diabetic patients. Am J Med 1986; 81: 630-634
40. Dahan M, Viron BM, Faraggi M et al. Diagnostic imaging and prognostic value of combined dipyridamole-exercise thallium imaging in haemodialysis patients. Kidney Int 1998; 54: 255-262
41. Rutsky EA, Rostand SG. The management of coronary artery disease in patients with end stage renal disease. In: Cardiac Dysfunction in Chronic Uremia. Kluwer Academic Publishers, Boston/Basle: 1992: 233-235
42. Reis G, Markovitz P, Leichtman A et al. Usefulness of Dobutamine stress echocardiography in detecting coronary artery disease in end stage renal disease. Am J Cardiol 1995; 75: 707-710
43. Ko W, Kreiger K, Isam O. Cardiopulmonary bypass procedures in dialysis patients. Ann Thorac Surg 1993; 55: 667-684
44. Owen C, Cummings R, Sell T, Schwab S, Jones R, Glower D. Coronary artery bypass grafting in patients with dialysis dependant renal failure. Ann Thorac Surg 1994; 58: 1729-1733
45. Kaul T, Fields B, Reddy M, Kahn D. Cardiac operations in patients with end stage renal disease. Ann Thorac Surg 1994; 57: 691-696
46. Rostand S, Kirk K, Rutsky E, Pacifico A. Results of coronary artery bypass grafting in end stage renal disease. Am J Kid Dis 1988; 12: 266-270
47. Weinrauch L, D'Elia J, Healy R et al. Asymptomatic coronary artery disease: Angiography in diabetic patients before renal transplantation. Ann Intern Med 1978; 88: 346-348
48. Reusser L, Osborn L, White H, Sexson R, Crawford M. Increased morbidity after coronary angioplasty in patients on chronic haemodialysis. Am J Cardiol 1994; 73: 965-967
49. Kahn J, Rutherford B, McConahay D, Johnson W, Giorgi L, Hartzler G. Short-and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J 1990; 119: 484-489
50. Rinehart A, Herzog C, Collins A, Flack J, Ma J, Opsahl J. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995; 25: 281-290
51. Fischman DL, Leon MB, Baim DS et al. for the stent restenosis study investigators. A randomised comparison of coronary stent placement and balloon angiopiasty in the treatment of coronary artery disease. New Engl J Med 1994; 331: 496-501
52. Manske C, Wang Y, Rector T, Wilson R, White C. Coronary revascularisation in insulin-dependant diabetic patients with chronic renal failure. Lancet 1992; 340: 998-1002
53. Verheught FWA. Acute coronary syndromes: drug treatments. Lancet 1999; 353 [suppl II]: 20-23
54. PRISM-PLUS Study Investigators. Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofibin in unstable angina and non Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497
55. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected myocardial infarction:collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322
56. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828
57. Swedberg K, Kjekshus J, Snappin S. Long term survival in severe heart failure in patients treated with enalapril-ten year follow-up of CONSENSUS-I. Eur Heart J 1999; 20: 136-139
58. Pitt B, Segal R, Martinez FA et al. Randomised trial of Losartan versus Captopril in patients over 65 with heart failure. (Evaluation of Losartan In the Elderly Study, ELITE). Lancet 1997; 349: 747-752
59. Isles CG, Walker LM, Beevers GD et al. Mortality in patients of the Glasgow blood pressure clinic. J Hypertension 1986; 4: 141-156
60. Brown JH, Hunt LP, Vites NP, Short C, Gokal R, Malik NP. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136-1142
61. Raine AEG, Margreiter R, Brunner FP et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7: 7-35